GRANT: LWF Doubles Down on Partnership with Aptadel Therapeutics (Barcelona, Spain)
LWF is proud to commit $680,000 to Aptadel Therapeutics to continue their ADEL-101 research. ADEL-101 is an aptamer-based drug conjugate (ApDC) a two-pronged therapeutic designed for precision targeting and tumor cell destruction.
LWF Grants $700,000 to Help Launch Multiple New Trials
In 2025–2026, the Little Warrior Foundation (LWF) is proud to announce a $700,000 grant to the Beat Childhood Cancer Foundation to support the launch of three new clinical trials, including two focused on DFMO with the Beat Childhood Cancer Research Consortium (BCCRC.)
Little Warrior Issues $100,000 Emergency Grant to Continue Precision Medicine Program
When we heard Dr. Maggie Fader’s precision medicine trial for kids with relapsed cancer was about to shut down due to NIH cuts, we called an emergency board meeting—and issued a $100,000 grant to keep it alive. This trial isn’t theoretical. It’s helping kids like Sasha, who was out of options, see real results right now. Hope doesn’t wait. And neither do we.
Little Warrior Commits $150,000 to MSK to Develop Fusion-Derived Cellular Immunotherapies
Little Warrior Foundation has awarded a $150,000, two-year grant to Dr. Swati Jain at Memorial Sloan Kettering Cancer Center (MSK). This project explores a cutting-edge concept in cancer treatment: the use of fusion-derived neoantigens as targets for immunotherapy.
Advancing ctDNA Testing for Ewing Sarcoma: A New Grant to DFCI
Little Warrior Foundation has awarded a $100,000 grant to Dr. Brian Crompton’s lab at Dana-Farber to develop a CLIA-certified liquid biopsy test for pediatric cancers. This breakthrough assay could transform diagnosis and treatment for Ewing sarcoma by enabling real-time, personalized care based on ctDNA levels.
GRANT: Aptadel Therapeutics (España) - $500,000
We are proud to announce our first international grant: a $500,000 commitment to Aptadel Therapeutics, based in Spain. This funding will support critical preclinical testing of an innovative new therapy, ADEL-101, that specifically targets the core genetic fusion fueling Ewing sarcoma.
SupraVax: Cleveland Clinic Ewing Sarcoma Vaccine Trial Update
Little Warrior Foundation has an update about the Personalized Vaccine Trial led by Dr. Pete Anderson and Dr. Timothy Chan and Cleveland Clinic known as the The SupraVax Trial.
Funding Philosophy: Valley of Death
At Little Warrior Foundation, we think about the entire path to the patient. That’s why we’re making bigger investments, like the $350,000 we granted this year or the $2.5 million we’ve committed to the upcoming vaccine trial. Translational medicine takes time — frustratingly so —but we have faith that these are necessary steps to avoid the Valley of Death.
Drugging The “Undruggable” - A New Grant from Little Warrior
Little Warrior Foundation grants $130,000 to John Bushweller, PhD, at the University of Virginia, to further optimize a small molecule inhibitor for ETS driven cancers like Ewing Sarcoma.